Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: Women's health initiative randomized trials

Journal of the National Cancer Institute

Volumn 103, Issue 19, 2011, Pages 1469-1475

  Tang, Jean Y ^a   Spaunhurst, Katrina M ^a,b   Chlebowski, Rowan T ^c   Wactawski Wende, Jean ^d   Keiser, Elizabeth ^a   Thomas, Fridtjof ^e   Anderson, Matthew L ^f   Zeitouni, Nathalie C ^d   Larson, Joseph C ^g   Stefanick, Marcia L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DEATH; ENDOMETRIUM CANCER; ENERGY EXPENDITURE; FEMALE; FOLLOW UP; HEALTH HAZARD; HIP FRACTURE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MELANOMA; MENOPAUSE; NON MELANOMA SKIN CANCER; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SELF REPORT; SKIN CANCER; SOLAR RADIATION; STROKE; WALKING; WOMEN'S HEALTH;

AGED; CONFOUNDING FACTORS (EPIDEMIOLOGY); ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MEDROXYPROGESTERONE ACETATE; MELANOMA; MENOPAUSE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; WOMEN'S HEALTH;

EID: 80054059515     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr333     Document Type: Article

References (39)

1. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283-287.
2. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129(7):1666- 1674.
3. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45-60. (Pubitemid 40029658)
4. Rosso S, Zanetti R, Martinez C, et al. The multicentre south European study 'Helios'. II: different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer. 1996;73(11):1447- 1454. (Pubitemid 26175684)
5. Verdier-Sevrain S, Yaar M, Cantatore J, Traish A, Gilchrest BA. Estradiol induces proliferation of keratinocytes via receptor-mediated mechanisms. FASEB J. 2004;18(11):1252-1254. (Pubitemid 39561567)
6. Plewig G, Cunliffe WJ, Binder N, Höschen K. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception. 2009;80(1):25-33.
7. Phillips T, Symons J, Menon S. Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. J Am Acad Dermatol. 2008;59(3):397-404.
8. Applebaum KM, Nelson HH, Zens MS, Stukel TA, Spencer SK, Karagas MR. Oral contraceptives: a risk factor for squamous cell carcinoma? J Invest Dermatol. 2009;129(12):2760-2765.
9. Asgari MM, Efird JT, Warton EM, Friedman GD. Potential risk factors for cutaneous squamous cell carcinoma include oral contraceptives: results of a nested case-control study. Int J Environ Res Public Health. 2010;7(2):427-442.
10. Gupta A, Driscoll MS. Do hormones influence melanoma? Facts and controversies. Clin Dermatol. 2010;28(3):287-292.
11. Mor Z, Caspi E. Cutaneous complications of hormonal replacement therapy. Clin Dermatol. 1997;15(1):147-154. (Pubitemid 27082296)
12. de Vries E, Nijsten TEC, Visser O, et al. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol. 2008;19(3):583-589. (Pubitemid 351325683)
13. Karagas MR, Stukel TA. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer. 2002;86(7):1085-1092. (Pubitemid 34438079)
14. Schmidt AN, Nanney LB, Boyd AS, King LE, Ellis DL. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol. 2006;15(12):971-980. (Pubitemid 44696115)
15. Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev. 1994;3(8):661-668. (Pubitemid 24377959)
16. Adami H-O, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer. 1989;44(5):833-839. (Pubitemid 20007980)
17. Koomen ER, Joosse A, Herings RMC, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol. 2009;20(2):358-364.
18. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
19. The Women's Health Initiative Study Group. Design of the Women's Health Initiative Clinical Trial and Observational Study. Control Clin Trials. 1998;19(1):61-109.
20. Tsai S, Stefanick M, Stafford R. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause. 2011;18(4):385-392.
21. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
22. Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003;13(S9):S122-S128. (Pubitemid 37324181)
23. Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer. 1977;36(6):804-809. (Pubitemid 8249819)
24. Beral V, Evans S, Shaw H, Milton G. Oral contraceptive use and malignant melanoma in Australia. Br J Cancer. 1984;50(5):681-685. (Pubitemid 15211639)
25. Holly EA, Weiss NS, Liff JM. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst. 1983;70(5):827-831. (Pubitemid 13101479)
26. Holman CD, Armstrong BK, Heenan PJ. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br J Cancer. 1984;50(5):673-680. (Pubitemid 15211638)
27. Gallagher RP, Elwood JM, Hill GB, Coldman AJ, Threlfall WJ, Spinelli JJ. Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada Melanoma Study. Br J Cancer. 1985;52(6):901-907. (Pubitemid 16229469)
28. Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer. 1988;42(6):821-824. (Pubitemid 19012906)
29. Smith MA, Fine JA, Barnhill RL, Berwick M. Hormonal and reproductive influences and risk of melanoma in women. Int J Epidemiol. 1998;27(5):751-757. (Pubitemid 28504960)
30. Lea CS, Holly EA, Hartge P, et al. Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am J Epidemiol. 2007;165(5):505-513. (Pubitemid 46340552)
31. Naldi L, Altieri A, Imberti G, Giordano L, Gallus S, Lavecchia C. Cutaneous malignant melanoma in women. phenotypic characteristics, sun exposure, and hormonal factors: a case-control study from Italy. Ann Epidemiol. 2005;15(7):545-550. (Pubitemid 40982131)
32. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer. 1996;67(3):327-332. (Pubitemid 26274121)
33. Lederman J, Lew R, Koh H, Sober AJ. Influence of estrogen administration on tumor characteristics and survival in women with cutaneous melanoma. J Natl Cancer Inst. 1985;74(5):981-985. (Pubitemid 15062954)
34. Rosso S, Zanetti R, Pippione M, Sancho-Garnier H. Parallel risk assessment of melanoma and basal cell carcinoma: skin characteristics and sun exposure. Melanoma Res. 1998;8(6):573-583. (Pubitemid 29046509)
35. Mancuso M, Gallo D, Leonardi S, et al. Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis. 2009;30(2):340-347.
36. Oliveria SA. Sun exposure and risk of melanoma. Arch Dis Child. 2005;91(2):131-138. (Pubitemid 43362517)
37. Ming ME, Levy RM, Hoffstad OJ, Filip J, Gimotty PA, Margolis DJ. Validity of patient self-reported history of skin cancer. Arch Dermatol. 2004;140(6):730-735. (Pubitemid 38747291)
38. Colditz GA, Martin P, Stampfer MJ, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol. 1986;123(5):894-900. (Pubitemid 16049247)
39. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. JAMA. 2011;305(13):1305-1314.